{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:06:22Z","timestamp":1792595182916,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005690","name":"Universit\u00e4t des Saarlandes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA)-directed positron emission tomography\/computed tomography (PET\/CT) has emerged as a highly accurate imaging modality for detecting tumor lesions in patients with biochemical recurrence (BCR) of prostate cancer (PC). While detection rates of lesions suspicious for PC relapse are known to increase with rising prostate-specific antigen (PSA) levels, data on the efficacy of PSMA PET\/CT at very low PSA values (\u2264\u20090.2 ng\/mL) remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this multicenter study, we analyzed 321 patients with BCR and a PSA value \u2264 0.2 ng\/mL across five German academic centers, using three different PSMA-targeted radiotracers: [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11, [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA I&amp;T, and [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 and analyzed the detection rates and potential predictive parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall pooled detection rate was 29.6%. No statistically significant differences in detection rates were observed between the three radiotracers ([\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11 29.4% vs. [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA I&amp;T, 22.5% vs. [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 32.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2265 0.314). Detection rates were significantly higher in patients with a PSA level\u2009&gt;\u20090.15 ng\/mL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029, \u03c6\u2009=\u20090.122), in those with an initial Gleason score\u2009&gt;\u20097 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018, \u03c6\u2009=\u20090.141) and in those receiving androgen deprivation therapy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.031, \u03c6\u2009=\u20090.120).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      All three radiotracers demonstrated comparable diagnostic performance, with no significant superiority observed between the\n                      <jats:sup>68<\/jats:sup>\n                      Ga- and\n                      <jats:sup>18<\/jats:sup>\n                      F-labeled tracers in the patient sample investigated (overall pooled detection rate: 29.6%). This positivity rate can serve as an expectation horizon for both the attending physician and the patient in the case of low PSA values. Further studies with larger cohorts, preferably conducted in a prospective setting, are needed to confirm and expand upon our findings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07292-1","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:41:57Z","timestamp":1745991717000},"page":"4368-4376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels\u2009\u2264\u20090.2 ng\/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&amp;T, and [18F]PSMA-1007"],"prefix":"10.1007","volume":"52","author":[{"given":"Caroline","family":"Burgard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madita","family":"Frei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Blickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela A.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Schreckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Rogasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Galler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-4099","authenticated-orcid":false,"given":"Florian","family":"Rosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"7292_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate Cancer. J Nucl Med. 2021;62:596\u2013604.","journal-title":"J Nucl Med"},{"key":"7292_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","volume":"79","author":"RE de Feria Cardet","year":"2021","unstructured":"de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, et al. Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging Cost-effective in prostate cancer: an analysis informed by the ProPSMA trial. Eur Urol. 2021;79:413\u20138.","journal-title":"Eur Urol"},{"key":"7292_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7292_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"7292_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","volume":"49","author":"F Khreish","year":"2022","unstructured":"Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49:1075\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7292_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate Cancer epidemiology and risk Factors-A systematic review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"7292_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","volume":"1","author":"GL Wright","year":"1995","unstructured":"Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urologic Oncology: Seminars Original Investigations. 1995;1:18\u201328.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"7292_CR8","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"7292_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637\u201340.","journal-title":"Urology"},{"key":"7292_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2019.04.004","volume":"130","author":"MA Hoffmann","year":"2019","unstructured":"Hoffmann MA, Wieler HJ, Baues C, Kuntz NJ, Richardsen I, Schreckenberger M. The impact of 68Ga-PSMA PET\/CT and PET\/MRI on the management of prostate Cancer. Urology. 2019;130:1\u201312.","journal-title":"Urology"},{"key":"7292_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.prnil.2020.07.008","volume":"9","author":"TN Kwan","year":"2021","unstructured":"Kwan TN, Spremo S, Teh AYM, McHarg D, Thangasamy I, Woo HH. Performance of Ga-68 PSMA PET\/CT for diagnosis and grading of local prostate cancer. Prostate Int. 2021;9:107\u201312.","journal-title":"Prostate Int"},{"key":"7292_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","volume":"56","author":"M Weineisen","year":"2015","unstructured":"Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-Labeled PSMA I&T: optimization of a PSMA-Targeted theranostic concept and first Proof-of-Concept human studies. J Nucl Med. 2015;56:1169\u201376.","journal-title":"J Nucl Med"},{"key":"7292_CR13","doi-asserted-by":"publisher","first-page":"684629","DOI":"10.3389\/fonc.2021.684629","volume":"11","author":"R Wang","year":"2021","unstructured":"Wang R, Shen G, Huang M, Tian R. The diagnostic role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET\/CT in the detection of prostate Cancer with biochemical recurrence: A Meta-Analysis. Front Oncol. 2021;11:684629.","journal-title":"Front Oncol"},{"key":"7292_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate Cancer-Updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and Meta-analysis. Eur Urol. 2020;77:403\u201317.","journal-title":"Eur Urol"},{"key":"7292_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate Cancer validated by histopathology. J Nucl Med. 2019;60:786\u201393.","journal-title":"J Nucl Med"},{"key":"7292_CR16","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","volume":"48","author":"A Afshar-Oromieh","year":"2021","unstructured":"Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021;48:2925\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 3","key":"7292_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/bju.13616","volume":"118","author":"G Meredith","year":"2016","unstructured":"Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, et al. The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016;118(Suppl 3):49\u201355.","journal-title":"BJU Int"},{"key":"7292_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286\u201394.","journal-title":"Lancet Oncol"},{"key":"7292_CR19","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cancers15051376","volume":"15","author":"C Burgard","year":"2023","unstructured":"Burgard C, Hoffmann MA, Frei M, Buchholz H-G, Khreish F, Marlowe RJ, et al. Detection efficacy of 68Ga-PSMA-11 PET\/CT in biochemical recurrence of prostate Cancer with very low PSA levels: A 7-Year, Two-Center Real-World. Experience Cancers (Basel). 2023;15:1376.","journal-title":"Experience Cancers (Basel)"},{"key":"7292_CR20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/snmmi procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7292_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","volume":"2","author":"PJL De Visschere","year":"2019","unstructured":"De Visschere PJL, Standaert C, F\u00fctterer JJ, Villeirs GM, Panebianco V, Walz J, et al. A systematic review on the role of imaging in early recurrent prostate Cancer. Eur Urol Oncol. 2019;2:47\u201376.","journal-title":"Eur Urol Oncol"},{"key":"7292_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/bju.13616","volume":"118","author":"G Meredith","year":"2016","unstructured":"Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, et al. The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016;118:49\u201355.","journal-title":"BJU Int"},{"key":"7292_CR23","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2967\/jnumed.117.192476","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate Cancer. J Nucl Med. 2017;58:1956\u201361.","journal-title":"J Nucl Med"},{"key":"7292_CR24","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.18632\/oncotarget.27239","volume":"10","author":"MA Hoffmann","year":"2019","unstructured":"Hoffmann MA, Buchholz H-G, Wieler HJ, H\u00f6fner T, M\u00fcller-H\u00fcbenthal J, Trampert L, et al. The positivity rate of 68Gallium-PSMA-11 ligand PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Oncotarget. 2019;10:6124\u201337.","journal-title":"Oncotarget"},{"key":"7292_CR25","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1007\/s00259-024-06674-1","volume":"51","author":"Y Wang","year":"2024","unstructured":"Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W, et al. The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET\/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET\/CT for early recurrent prostate cancer patients with PSA\u2009<\u20090.2 Ng\/mL after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51:2484\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7292_CR26","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00259-023-06185-5","volume":"50","author":"N Solomonidou","year":"2023","unstructured":"Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, et al. PSMA-PET\/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA\u2009<\u20090.2 Ng\/ml. Eur J Nucl Med Mol Imaging. 2023;50:2529\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7292_CR27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s00259-016-3572-5","volume":"44","author":"C Berliner","year":"2017","unstructured":"Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, et al. Detection rate of PET\/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. Eur J Nucl Med Mol Imaging. 2017;44:670\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7292_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ph15010009","volume":"15","author":"F G\u00fchne","year":"2022","unstructured":"G\u00fchne F, Radke S, Winkens T, K\u00fchnel C, Greiser J, Seifert P, et al. Differences in distribution and detection rate of the [68Ga]Ga-PSMA ligands PSMA-617, -I&T and\u2013\u200911\u2014Inter-Individual comparison in patients with biochemical relapse of prostate Cancer. Pharmaceuticals. 2022;15:9.","journal-title":"Pharmaceuticals"},{"key":"7292_CR29","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/jcm11175064","volume":"11","author":"MA Hoffmann","year":"2022","unstructured":"Hoffmann MA, M\u00fcller-H\u00fcbenthal J, Rosar F, Fischer N, von Eyben FE, Buchholz H-G, et al. Primary staging of prostate Cancer patients with [18F]PSMA-1007 PET\/CT compared with [68Ga]Ga-PSMA-11 PET\/CT. J Clin Med. 2022;11:5064.","journal-title":"J Clin Med"},{"key":"7292_CR30","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","volume":"48","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:2978\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7292_CR31","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1007\/s00259-022-05925-3","volume":"49","author":"F Rosar","year":"2022","unstructured":"Rosar F, Schaefer-Schuler A, Bartholom\u00e4 M, Maus S, Petto S, Burgard C, et al. [89Zr]Zr-PSMA-617 PET\/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates. Eur J Nucl Med Mol Imaging. 2022;49:4736\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7292_CR32","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1007\/s00259-023-06241-0","volume":"50","author":"F Rosar","year":"2023","unstructured":"Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, et al. Detection efficacy of [89Zr]Zr-PSMA-617 PET\/CT in [68Ga]Ga-PSMA-11 PET\/CT-negative biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:2899\u2013909.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7292_CR33","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3390\/diagnostics14202321","volume":"14","author":"MB Bastian","year":"2024","unstructured":"Bastian MB, Burgard C, Blickle A, Speicher T, Ezziddin S, Rosar F. [89Zr]Zr-PSMA-617 PET\/CT in a patient with biochemical recurrence of prostate Cancer and prior indetermined findings on [18F]PSMA-1007 imaging. Diagnostics. 2024;14:2321.","journal-title":"Diagnostics"},{"key":"7292_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s40644-024-00778-5","volume":"24","author":"C Burgard","year":"2024","unstructured":"Burgard C, Rosar F, Larsen E, Khreish F, Linxweiler J, Marlowe RJ, et al. Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET\/CT in early biochemical recurrence of prostate cancer. Cancer Imaging. 2024;24:132.","journal-title":"Cancer Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07292-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:36:28Z","timestamp":1759394188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07292-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7292"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07292-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the authorized and responsible institutions:Institutional Review Board of the \u00c4rztekammer des Saarlandes\/Saarbr\u00fccken (approval number: 170\/22, approval date: 13th September 2022), the ethics committee of the Medical Association North Rhine (Aekno) (approval number: 41\/2019, approval date: 22nd February 2019), the ethics committee of the Medical Association Rhineland-Palatinate (Laek Rlp) (approval number: 2018\/13390, approval date: 29th October 2018), the ethics committee of the Ludwig-Maximilians University (approval number: 21\u20130053, approval date: 26th February 2024), local ethics committee W\u00fcrzburg (waiver number: 20230223 02), ), the ethics commission of the Charit\u00e9\u2013 Universit\u00e4tsmedizin Berlin (approval number: EA4\/225\/23, approval date: 7th December 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Informed consent was obtained from all subjects involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Parts of the cohort analyzed here were originally described in a previous publication by our group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency statement"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}